24 articles found
Browse Rainier Rehab's editorial coverage of Psychedelics. Our writers track federal and state policy, peer-reviewed research, treatment innovations, and frontline reporting from the addiction recovery field. Each article in this collection cites primary sources — government datasets (SAMHSA, NIH, CDC), Medicaid and Medicare bulletins, JAMA and Lancet studies, and on-the-record statements from clinicians, regulators, and people in recovery — so readers can verify claims and dig deeper.
We update this tag whenever new psychedelics reporting publishes. If you're a researcher, journalist, or family member trying to make sense of substance use disorder treatment, this is the working archive. For a directory of accredited treatment facilities, visit our facilities directory; to compare modalities, see our treatments overview and levels of care guide.
Single dose of psilocybin with therapy support produced rapid, sustained reductions in suicidal thoughts among treatment-resistant patients
The Department of Veterans Affairs begins groundbreaking clinical trial testing MDMA-assisted therapy for veterans struggling with PTSD and alcohol use disorder, marking a significant federal investment in psychedelic medicine.
University of Reading study finds single psilocybin dose reduces neuropathic pain for weeks and makes standard painkillers work better.
Researchers create a new class of compounds that activate serotonin receptors linked to brain healing without causing hallucinations, potentially opening addiction treatment to broader populations.
First randomized double-blind study in Sweden finds psilocybin provides clinically meaningful depression relief within days, with 53% remission rate at six weeks.
UC San Francisco and Imperial College London researchers discover that one 25mg dose of psilocybin creates measurable anatomical brain changes lasting at least a month.
JAMA study finds psychedelic-assisted therapy produced higher abstinence rates and longer relapse prevention than standard treatment
Tennessee becomes latest state to legalize FDA-approved ibogaine research, joining Texas and Arizona in studying the psychedelic for PTSD and opioid addiction treatment.
Texas is developing a medical psilocybin program to treat depression, PTSD, and substance use disorders, with support from Trump's executive order and FDA fast-tracking.
Agency accelerates regulatory action on psilocybin, methylone, and noribogaine following Trump executive order, issuing priority vouchers and clearing Phase 1 studies.
In a historic first, the FDA clears DemeRx's noribogaine hydrochloride for Phase I study, marking the first US clinical trial of an ibogaine-derived compound for addiction treatment.
President Trump signed an executive order accelerating psychedelic drug research, directing FDA priority vouchers, Right to Try access, and $50 million in federal-state partnerships.
White House prepares executive order to fund research into ibogaine for PTSD and traumatic brain injury, potentially opening new avenues for addiction treatment research.
Lykos Therapeutics slashes workforce by 75% after Complete Response Letter reveals FDA concerns about trial design and durability, forcing psychedelic research firms to reconsider regulatory strategy.
Compass Pathways' COMP360 psilocybin therapy achieves primary endpoints in two Phase 3 trials for treatment-resistant depression, with FDA submission planned for late 2026.
Federal agencies announce unprecedented collaboration to research and deploy rapid-acting mental health treatments for veterans suffering from PTSD and serious mental health conditions.
Congress introduces IBOGAINE Act to protect veterans' access to psychedelic treatments for PTSD and addiction, building on Trump's executive order.
Starting July 1, Connecticut becomes one of the first states to offer state-funded psilocybin therapy through a regulated medical program, with high demand already evident.
Louisiana's groundbreaking pilot program will use opioid settlement funds to research psilocybin, ibogaine, and MDMA as treatments for addiction and mental health conditions.
FDA priority review vouchers could bring first psychedelic-assisted therapies to market within months, potentially transforming treatment for depression, PTSD, and substance use disorders.
University of Southern California receives funding to launch its first clinical study of psilocybin-assisted therapy combined with mindfulness meditation for mental well-being.
A randomized quadruple-blind trial found psilocybin-assisted therapy achieved 30% complete abstinence at 180 days vs 0% with placebo, with 72% reduced relapse risk.
State lawmakers pass bill to study psychedelic-assisted therapy, joining growing national movement to explore alternative treatments for substance use disorders and mental health conditions.
The Department of Veterans Affairs begins enrolling 80 veterans in a groundbreaking study combining MDMA with psychotherapy to treat co-occurring PTSD and alcohol use disorder.